Company intelligence / Profile preview
Portage Biotech
Westport, Connecticut, USAportagebiotech.com ↗
- Ownership
- Public · PRTG
- Development stage
- Other
01
Overview
Portage Biotech has a portfolio of five diverse drug platforms with ten products in preclinical or clinical development. Notable results include promising preclinical data for PORT-7 (adenosine A2B inhibitor) outperforming anti-PD1 antibody in a mesothelioma mouse model. The company’s lead iNKT engager program PORT-3 has entered Phase I trials. The company employs a “fail-fast” approach to select the most promising assets for advancement and commercialization
- Therapeutic areas
- Oncology
- Modalities
- Immunotherapiessmall molecules (adenosine receptor antagonists)iNKT cell engagers
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Portage Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Portage Biotech.